MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial

Trial Profile

MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2018

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Acronyms COLUMBA
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 May 2018 Results assessing the durability of Clinical Response, presented at the 114th International Conference of the American Thoracic Society
    • 23 May 2018 Long-term safety results presented at the 114th International Conference of the American Thoracic Society
    • 21 May 2018 According to a GlaxoSmithKline media release, Dr. Sumita Khatri, Associate Professor of Medicine at Cleveland Clinic, Ohio is a principle investigator of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top